VIDEO: High-dose risankizumab safe, effective treatment for plaque psoriasis
Click Here to Manage Email Alerts
In this Healio exclusive video, Steven R. Feldman, MD, PhD, discussed psoriasis research from the phase 2 KNOCKOUT study presented at the American Academy of Dermatology Annual Meeting.
Feldman, professor of dermatology, pathology and social sciences and health policy at Wake Forest University School of Medicine, discussed findings from the study that examined whether moderate to severe plaque psoriasis could be effectively “cured” with a high upfront dose of the interleukin-23 blocker risankizumab (Skyrizi, AbbVie).
“The IL-23 blocker looks pretty safe so far, and even at this higher dose, it still looks very safe, and it looks like it can be even more effective than what we’ve been giving people if we use it with this high dose. I think people would be really happy with that,” Feldman said.
Collapse
Read more about
Click Here to Manage Email Alerts